Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
95 hedge funds and large institutions have $98.2M invested in Seelos Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 15 closing their positions.
221% more call options, than puts
Call options by funds: $2.08M | Put options by funds: $648K
50% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 22
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
3% more funds holding
Funds holding: 92 → 95 (+3)
9% less capital invested
Capital invested by funds: $108M → $98.2M (-$9.28M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$2.98M |
| 2 |
BlackRock
New York
|
+$2.33M |
| 3 |
Two Sigma Advisers
New York
|
+$1.8M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$1.75M |
| 5 |
State Street
Boston,
Massachusetts
|
+$894K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$4.09M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$3.56M |
| 3 |
Morgan Stanley
New York
|
-$1.86M |
| 4 |
Two Sigma Investments
New York
|
-$1.85M |
| 5 |
Millennium Management
New York
|
-$1.18M |
SEEL Hedge Fund Activity: Q3 2021 in Review
95 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2021, worth a combined $98.2M — down 8.6% from $108M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new SEEL positions and 15 closed out — a net gain of 4 holders — while 33 added to existing stakes and 22 trimmed.
The largest buyer was Woodline Partners, adding an estimated $2.98M. The largest seller was J. Goldman & Co, cutting an estimated $4.09M.
- 95 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2021, up from 92 in Q2 2021.
- Funds reported $98.2M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2021, down 8.6% quarter-over-quarter.
- 19 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2021 and 15 closed out, a net change of +4 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2021 was Woodline Partners, an estimated $2.98M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2021 was J. Goldman & Co, an estimated $4.09M sold.
Based on aggregated 13F filings for Q3 2021.